BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 22018148)

  • 1. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minority issues in prostate disease.
    French DB; Jones LA
    Med Clin North Am; 2005 Jul; 89(4):805-16. PubMed ID: 15925651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial results did not resolve controversies surrounding prostate cancer screening.
    Hoffman RM
    Curr Opin Urol; 2010 May; 20(3):189-93. PubMed ID: 20224414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Screening for prostate cancer: an up date].
    Ito K
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):33-7. PubMed ID: 22241351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
    Kell JS
    Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
    Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
    CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen best practice statement: 2009 update.
    Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
    J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landmarks in prostate cancer screening.
    Schröder FH
    BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA screening: determinants of primary-care physician practice patterns.
    Tasian GE; Cooperberg MR; Potter MB; Cowan JE; Greene KL; Carroll PR; Chan JM
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):189-94. PubMed ID: 22343837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance with biopsy recommendations of a prostate cancer risk calculator.
    van Vugt HA; Roobol MJ; Busstra M; Kil P; Oomens EH; de Jong IJ; Bangma CH; Steyerberg EW; Korfage I
    BJU Int; 2012 May; 109(10):1480-8. PubMed ID: 21933335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen best practice statement: 2009 update.
    Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P;
    J Urol; 2013 Jan; 189(1 Suppl):S2-S11. PubMed ID: 23234625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline update: what's the best approach for screening asymptomatic men for prostate cancer?
    Holten KB; Al-Abdulla S
    J Fam Pract; 2009 Dec; 58(12):E2. PubMed ID: 19961813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.